Clinical trial
Treatment With Plerixafor in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given With A Mobilizing Regimen of Chemotherapy and G-CSF
NCT00322387 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment With Plerixafor in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given With A Mobilizing Regimen of Chemotherapy and G-CSF
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2004
- Completion date
- July 31, 2006
- Enrollment
- 40 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.